Kazia Therapeutics (KZIA) Cash & Equivalents (2017 - 2025)

Kazia Therapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $2.8 million for Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 152.18% year-over-year to $2.8 million; the TTM value through Jun 2025 reached $2.8 million, up 152.18%, while the annual FY2025 figure was $2.8 million, 152.18% up from the prior year.
  • Cash & Equivalents reached $2.8 million in Q2 2025 per KZIA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $5.3 million in Q2 2022 to a low of $1.1 million in Q2 2024.
  • Average Cash & Equivalents over 4 years is $3.2 million, with a median of $3.1 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: crashed 68.83% in 2024, then surged 152.18% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $5.3 million in 2022, then plummeted by 33.56% to $3.5 million in 2023, then plummeted by 68.83% to $1.1 million in 2024, then soared by 152.18% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Cash & Equivalents are $2.8 million (Q2 2025), $1.1 million (Q2 2024), and $3.5 million (Q2 2023).